Allergan (AGN) Announces U.S. Launch of JUVÉDERM VOLBELLA XC
- Record-setting rally pushes on as S&P ends week up 3 percent
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- Unusual 11 Mid-Day Movers: (IDXG) (INVN) (EBS) Higher; (SCON) (DTEA) (DLTH) Lower (more...)
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Allergan plc, (NYSE: AGN) announced that the latest addition to the JUVÉDERM® collection of fillers, JUVÉDERM VOLBELLA XC, is now available to physicians and patients for use in the lips for lip augmentation and for correction of perioral rhytids, commonly referred to as "lipstick lines", in adults over the age of 21.1 In clinical trials, JUVÉDERM VOLBELLA® XC was found to effectively increase lip fullness and soften the appearance of lines around the mouth in a majority of subjects through one year.1,2* JUVÉDERM VOLBELLA® XC is the only filler proven to last through one year in both the lips and perioral rhytids with optimal treatment.2
"Our physician customers have told us perioral lines are difficult to treat and are also a top concern among patients," said David Moatazedi, Senior Vice President US Medical Aesthetics. "We developed a soft, smooth gel appropriate for adding subtle volume to the lips and softening the appearance of perioral lines to address this specific need. We are committed to providing our doctors with products to address the evolving needs of their aesthetically-oriented patients."
According to the American Society of Plastic Surgeons (ASPS), use of soft tissue fillers in 2015 was the fastest growing cosmetic minimally-invasive procedure.3 JUVÉDERM VOLBELLA® XC is approved specifically for the lips and perioral rhytids. JUVÉDERM VOLBELLA® XC is formulated with VYCROSS®,2 a proprietary filler technology from Allergan, which yields smooth products that have been engineered to address specific patient concerns.4 " The most common side effects observed in clinical trials were temporary responses at the treatment site such as swelling, tenderness, bruising, firmness lumps/bumps, redness, pain, discoloration, itching and dryness. Most of these side effects resolved within 30 days.2
JUVÉDERM VOLBELLA® XC is now available for purchase by physicians who have completed an online training program. Physicians can find information about injection technique and complete the online training by visiting www.VolbellaTraining.com.
Consumers can learn more about JUVÉDERM VOLBELLA® XC and the JUVÉDERM® collection of fillers or find a doctor in their area by visiting www.juvederm.com.al Filler Technology, 2013.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Allergan's (AGN) patents on Restasis to be reviewed at U.S. agency - Bloomberg
- Allergan Comments on PTAB Decision Regarding Mylan's Petitions for Inter Partes Review (IPR) of RESTASIS® Patents
- Aegon Accelerates Execution of Strategy and Increases Expense Savings
Create E-mail Alert Related CategoriesCorporate News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!